| Not Yet Recruiting | PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) NCT07477418 | University of Vermont | Phase 1 / Phase 2 |
| Not Yet Recruiting | Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer NCT07036978 | Chang Gung Memorial Hospital | — |
| Recruiting | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Ad NCT07491445 | Revolution Medicines, Inc. | Phase 3 |
| Recruiting | A Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) NCT07450859 | BicycleTx Limited | Phase 2 |
| Not Yet Recruiting | How Does Pre-operative Biliary Drainage in Pancreatic Adenocarcinoma Affect Surgical Outcomes in Pancreatic Ca NCT07444840 | East Lancashire Hospitals NHS Trust | — |
| Not Yet Recruiting | Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT07435038 | Betta Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC NCT07155850 | BetaGlue Therapeutics SpA | N/A |
| Recruiting | Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma NCT07480928 | Beijing Biotech | Phase 1 / Phase 2 |
| Recruiting | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors NCT07349537 | Revolution Medicines, Inc. | Phase 1 |
| Recruiting | Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis NCT07030283 | University of Colorado, Denver | Phase 1 |
| Not Yet Recruiting | A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer NCT07301229 | Shanghai Henlius Biotech | Phase 2 |
| Recruiting | A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal NCT07235202 | Shenzhen Majory Biotechnology Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC) NCT07217717 | SOFIE | Phase 3 |
| Recruiting | A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined Wi NCT07255404 | BioNTech SE | Phase 2 |
| Recruiting | Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) NCT06659705 | Institut Curie | Phase 2 |
| Not Yet Recruiting | Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life NCT07255001 | British Columbia Cancer Agency | N/A |
| Recruiting | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Ca NCT07223047 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Recruiting | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer NCT07227168 | Sutro Biopharma, Inc. | Phase 1 |
| Not Yet Recruiting | A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers NCT07233850 | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 |
| Enrolling By Invitation | Early Recurrence After Surgery for Pancreatic Cancer NCT07241676 | Azienda Ospedaliera di Padova | — |
| Recruiting | To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. NCT07303465 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies NCT07014254 | Xijing Hospital | N/A |
| Recruiting | A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521 | Tanabe Pharma America, Inc. | Phase 1 / Phase 2 |
| Enrolling By Invitation | Selective Plasma Adsorption of Extracellular DNA in Prevention of Intraoperative Metastasis in Pancreatic Canc NCT06967662 | Ilyinskaya Hospital, JSC | N/A |
| Recruiting | Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT06895031 | Guangzhou JOYO Pharma Co., Ltd | Phase 2 |
| Enrolling By Invitation | A Study on Multimodal Prognostic Scoring of Advanced PDAC. NCT07373691 | RenJi Hospital | — |
| Recruiting | HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinom NCT06773130 | West China Hospital | Phase 1 / Phase 2 |
| Recruiting | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) NCT06710132 | EMD Serono Research & Development Institute, Inc. | Phase 1 / Phase 2 |
| Recruiting | Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer NCT06639724 | University of California, San Diego | Phase 1 |
| Terminated | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Mono NCT06599502 | AstraZeneca | Phase 1 |
| Not Yet Recruiting | Innovative Therapeutic Treatments to Inhibit Perineural Invasion in Pancreatic Adenocarcinoma NCT06616688 | IRCCS San Raffaele | — |
| Completed | OSCAR I STUDY - The ONCObind CTC Removal Study NCT06481397 | ExThera Medical Corporation | N/A |
| Recruiting | A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer NCT07224750 | City of Hope Medical Center | — |
| Not Yet Recruiting | Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer NCT06361030 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Recruiting | A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma NCT06261359 | Qilu Pharmaceutical Co., Ltd. | Phase 2 |
| Not Yet Recruiting | "Effect of Screening Using Imaging (CT/ EUS) on Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in NCT06044064 | Asian Institute of Gastroenterology, India | — |
| Recruiting | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors NCT06026410 | Kura Oncology, Inc. | Phase 1 |
| Recruiting | ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) NCT06182072 | ProDa BioTech, LLC | Phase 1 |
| Recruiting | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors NCT06040541 | Revolution Medicines, Inc. | Phase 1 |
| Recruiting | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, NCT05706129 | ITM Oncologics GmbH | Phase 1 / Phase 2 |
| Terminated | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours NCT05605522 | 3B Pharmaceuticals GmbH | Phase 1 |
| Recruiting | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT05379985 | Revolution Medicines, Inc. | Phase 1 / Phase 2 |
| Completed | Microbiota and Metabolites Alterations in Pancreatic Head and Body/Tail Cancer Patients NCT06147154 | Qilu Hospital of Shandong University | — |
| Recruiting | RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer NCT04575363 | CHU de Reims | N/A |
| Recruiting | EUS-RFA PANCARDINAL-1 Trial NCT04990609 | The University of Texas Health Science Center, Houston | Phase 2 |
| Unknown | Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer NCT05201729 | Ruijin Hospital | — |
| Unknown | PRedictiOn Algorithms for the DeTECTion of Early Stage Pancreatic Cancer NCT04883450 | Kaiser Permanente | — |
| Unknown | Clinical and Multiomics Study of First-line Chemotherapy for Advanced Pancreatic Cancer NCT05168254 | Ruijin Hospital | — |
| Recruiting | Advanced Therapies for Liver Metastases NCT04622423 | IRCCS San Raffaele | — |
| Active Not Recruiting | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors NCT04083599 | Genmab | Phase 1 / Phase 2 |
| Recruiting | Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer NCT03977233 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Completed | Study on Single-cell Regulons Atlas of Pancreatic Ductal Adenocarcinoma NCT06720454 | Tiejun Ying | — |
| Completed | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors NCT03811652 | MedImmune LLC | Phase 1 |
| Terminated | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Mal NCT03549000 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadju NCT07329920 | Guo ShiWei | — |
| Completed | Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Panc NCT03032913 | University Hospital, Bordeaux | — |
| Terminated | Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study NCT02782182 | University of Chicago | Phase 1 |